Suggestions
Curtis Layton
CEO, Co-Founder at Protillion Biosciences
Curtis Layton is the CEO and Co-Founder of Protillion Biosciences, a biotechnology company he founded in 2019.12 He holds a Ph.D. in Computational Biology (Biochemistry) from Duke University, completed postdoctoral fellowships in Genetics and Biochemistry at Stanford University School of Medicine, and has a B.S. in Zoology from Brigham Young University.
Layton has pioneered high-impact technology approaches to drug discovery, leveraging interdisciplinary methods including protein engineering, next-generation sequencing, molecular biology, and computational biology.3 His work at Protillion focuses on commercializing disruptive technology for therapeutic antibody and binder discovery.2
Prior to founding Protillion, Layton worked as a Research Scientist and Postdoctoral Research Fellow at Stanford University School of Medicine from 2011 to 2019.6 During his time at Stanford, he developed the founding technology for Protillion.3
Under Layton's leadership, Protillion has developed a novel, high-throughput protein display platform designed to revolutionize traditional approaches to the design and development of protein-based drugs.2 The company's technology can characterize the binding affinity of approximately 1 million antibody variants in a 2-day automated run, significantly accelerating the process of identifying optimal antibody candidates.4
In December 2022, Protillion raised $18 million in Series A financing led by ARCH Venture Partners and Illumina Ventures to scale its hardware infrastructure and development teams.45
Highlights


